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Abstract 
Introduction: Brain metastasis is common in relapsed neuroblastoma patients, but the characteristics of brain 
metastasis remain largely unknown. This study aimed to investigate the status of brain metastasis with neuroblastoma 
in South China.
Methods: In this retrospective case‑based study, 106 patients with stage 4 neuroblastoma from the Department of 
Pediatric Oncology in Sun Yat‑sen University Cancer Center between January 2004 and May 2013 were included. The 
incidence, risk factors, and survival status of these patients were reviewed and analyzed.
Results: Of the 106 patients, 11 (10.4%) developed brain metastasis, accounting for 20.0% of 55 patients with relapse 
or progression. The age at initial diagnosis of the 11 patients ranged from 2 to 10 years (median 4 years), which 
was younger than that of the patients without brain metastasis (median 5 years, range 1–10 years, P = 0.073). The 
male to female ratio of the 11 patients was 8:3, which was not significantly different from that of the patients with‑
out brain metastasis (P = 0.86). Patients with brain metastasis had higher lactate dehydrogenase levels than those 
without brain metastasis, but the differences were not significant (P = 0.076). Eight patients died, and 3 patients 
survived. The median interval from the initial diagnosis to the development of brain metastasis was 18 months (range 
6–32 months). The median survival was 4 months (range 1 day to 29 months) after the diagnosis of brain metastasis. 
The median interval from the manifestation of brain metastasis to death was 3 months (range 1 day to 11 months).
Conclusions: High‑risk factors for brain metastasis in cases of neuroblastoma include bone marrow involvement and 
a younger age at initial diagnosis. Nevertheless, multiple treatment modalities can improve disease‑free survival.
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Introduction
Neuroblastoma is a type of extracranial solid tumor that 
is most commonly observed in children. Neuroblastoma 
cells arise from the adrenal medulla or paraspinal sites 
where sympathetic nervous system tissue is located. The 
heterogeneous biological behavior of this tumor var-
ies in terms of clinical course. Their broad spectrum of 
clinical behavior ranges from spontaneous regression 
to differentiation to benign ganglioneuroblastoma or 
ganglioneuroma, or to aggressive invasion with metas-
tases to the liver, bone, bone marrow, and central nerv-
ous system (CNS). Approximately 60% of patients with 
stage 4 neuroblastoma achieve complete remission with 
multidisciplinary treatment, which involves chemo-
therapy, surgery, radiation, hematopoietic stem cell 
transplantation, and maintenance therapy including 
immunotherapy [1]. Although the survival of patients 
with high-risk neuroblastoma has improved [2], most 
patients eventually died from relapse. Relapsed neuro-
blastoma metastasizes to the CNS as one cause of death. 
The overall incidence of brain metastasis in neuroblas-
toma after treatment ranges from 1.7% to 11.7% [3].
No systemic study of metastasis to the CNS 
as the main site of progression or recurrence in 
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neuroblastoma patients has been reported in China. 
We retrospectively analyzed the disease progression, 
recurrence, and metastases to the brain parenchyma, 
intraventricular areas, and medulla oblongata in 
patients with relapsed neuroblastoma at the Depart-
ment of Pediatric Oncology in Sun Yat-sen University 
Cancer Center (SYSUCC). Our study aimed to gain 
insight into the incidence, risk factors, and prognosis 




The clinical data of eligible patients with stage 4 neu-
roblastoma who were treated at the Department of 
Pediatric Oncology in SYSUCC between January 2004 
and May 2013 were collected. These patients met the 
following criteria: (a) the patients with stage 4 neu-
roblastoma were younger than 18  years at the initial 
diagnosis; (b) brain metastasis was not observed at 
initial diagnosis; (c) the patients achieved complete 
response (CR) or partial response (PR) or had stable 
disease (SD) at the primary sites after multidiscipli-
nary treatment according to the International Neuro-
blastoma Response Criteria [4]; and (d) the patients 
experienced the first occurrence of brain involvement 
after they achieved CR, PR or SD. The patients with 
primary brain tumors and those who had intracra-
nial leptomeningeal metastasis or direct extension of 
tumors from the adjacent skull or dura mater were 
excluded.
MYCN status and staging
The MYCN amplification was detected by fluorescence 
in  situ hybridization in neuroblastoma samples after 
2008. The staging evaluation was performed according to 
the International Neuroblastoma Staging System (INSS) 
[5]. Any primary neuroblastoma with dissemination to 
distant lymph nodes, the bone, bone marrow, liver, skin, 
and/or other organs was classified as stage 4 tumor.
Definition of brain metastasis
The diagnosis of brain metastasis was based on clinical 
characteristics and magnetic resonance imaging (MRI) 
results if cerebral biopsy was infeasible. The clinical 
symptoms of patients with brain metastasis included 
headache and vomiting. The MRI of brain metastasis 
showed that intracranial metastases were localized to 
the parenchyma, ventricles, leptomeninges, and medulla 
oblongata [6]. Pathologic diagnosis of brain metastasis 
was performed by detecting the surgical specimens.
Treatment
Patients with high-risk stage 4 neuroblastoma, received 
multidisciplinary treatment including chemotherapy, sur-
gery, radiotherapy, autologous stem cell transplant (ASCT), 
and maintenance therapy including immunotherapy.
Chemotherapy
Four to six cycles of induction chemotherapy were 
administered prior to surgery. First-line chemotherapy 
consisted of vincristine 1.5 mg/m2 on day 1, cyclophos-
phamide 1.2–1.5 g/m2 on day 1, and doxorubicin 50 mg/
m2 on day 1 (CAV regimen), or cisplatinum 20 mg/m2 on 
days 1–5 and etoposide 100 mg/m2 on days 1–5 (EP regi-
men)/etoposide 100  mg/m2 on days 1–4 and ifosfamide 
1500 mg/m2 on days 1~4 and cisplatinum 20 mg/m2 on 
days 1~4 (VIP regimen), which were alternately admin-
istered at 3-week intervals. CAV and EP regimen were 
alternately administered at 3-week intervals before 2010. 
CAV and VIP regimen were alternately administered at 
3-week intervals after 2010. 
Surgery
An evaluation of extensive disease was performed after 
induction chemotherapy. Patients underwent surgery 
to remove the primary tumor as completely as possible. 
Evaluation of the extent of the tumor excision was based 
on the Shamberger criteria [7]; the tumors were classified 
into three types: complete resection without macroscopic 
residual tumor, subtotal resection with ≤20% residual 
tumor, and partial resection with 21%–50% residual tumor.
Radiotherapy
Radiotherapy was performed as consolidation therapy 
after chemotherapy and surgery. The target volume was 
delineated according to the imaging examination and 
surgery documentation. The target volume included the 
primary lesion. The lymphatic drainage area was cov-
ered if lymph node involvement was suspected. The pre-
scribed doses were 1.8–2.0  Gy/d by using 6.0–8.0 MV 
X-ray and 18.0–40.0  Gy in total (median 25.6  Gy) with 
intensity-modulated radiation therapy (IMRT) [7].
Autologous stem cell transplant (ASCT)
ASCT was performed in the patients with CR before 
2008. The conditioning regimen included melphalan, car-
boplatin and etoposide.
Maintenance therapy
13-cis-retinoic acid was administered to high-risk 
patients following the completion of consolidation ther-
apy. The dosage of 13-cis-retinoic was 100–160 mg/m2 in 
two divided doses for consecutive 7 days every 14 days, 
lasting 1 year.
Page 3 of 7Zhu et al. Chin J Cancer  (2015) 34:49 
Immunotherapy consisting of amplified human leuko-
cyte antigen (HLA)-haploidentical donor immune cell 
infusion, cytokine-induced killer (CIK) cells, or natural 
killer (NK) cells was administered to selected patients 
with minimal residual disease or those who achieved CR 
after completion of chemotherapy, surgery, and radio-
therapy [1]. One patient received anti-GD2 antibody 
immunotherapy in Hong Kong University.
Salvage therapy
When brain metastasis or recurrence occurred, salvage 
therapy including surgery, radiotherapy, and chemother-
apy was administered.
Salvage radiotherapy: Patient 5 received radiotherapy 
2  months after surgery. Patient 4 received radiotherapy 
20 days after surgery. The radiotherapy for other patients 
is shown in Table 1.
Salvage chemotherapy: Six patients were treated 
with 2 cycles (range 1–6 cycles) of chemotherapy that 
consisted of temozolomide and irinotecan at 3-week 
intervals; a combination of vincristine 1.5  mg/m2 on 
day 1, irinotecan 20  mg/m2 on days 1–5, and temozo-
lomide 100 mg/m2 on days 1–5 administered 1 h before 
irinotecan.
Follow‑up
Follow-up was performed by telephone, by mail, and in 
the clinic. The date of the last follow-up was December 
31, 2013. The follow-up period was calculated from the 
time of initial diagnosis to death or the last follow-up, 
whichever occurred first.
Statistical analysis
The Kaplan–Meier method was used to calculate the 
overall survival (OS) and event-free survival (EFS). A Chi 
square test was used to compare variables in two depend-
ent groups, and the Wilcoxon test was used to compare 
the age distribution between the presence and absence of 
brain metastasis. A value of P < 0.05 was considered sta-
tistically significant.
Results
Patient characteristics and outcomes after initial treatment
A total of 106 patients with stage 4 neuroblastoma 
were involved in this study. The patients comprised 70 
boys and 36 girls, with a median age of 6  years (range 
1–18 years).
Of the 106 children, 81 (76.4%) achieved CR, PR, or SD 
after multidisciplinary treatments. Twelve patients with 
CR received ASCT. After the completion of multidisci-
plinary treatment, all patients underwent maintenance 
therapy and were therefore followed up. The 5-year OS 
rate in patients who achieved the first CR or good PR was 
45.9%. Of the 81 patients, 55 developed disease relapse 
and progression, including 11 patients who developed 
brain metastasis (Table 2).
Of the 11 patients whose brains were the initial site of 
recurrence or progression, 8 were boys and 3 were girls, 
with a median age of 4 years (range 2–10 years). Of the 
other 44 patients with initial relapse or progression at 
other sites, 30 were boys and 14 were girls, with a median 
age of 5 years (range 1–10 years). The overall incidence of 
CNS metastasis was 10.4% (11/106) in patients with stage 
Table 1 Treatment strategies and outcomes of 8 patients with brain metastasis
IFO ifosfamide, VM26 teniposide, TMZ temozolomide, CPT-11 irinotecan, VIP etoposide, ifosfamide, and cisplatinum, VCR vincristine.
Patient no. Metastatic site Surgery Radiotherapy Chemotherapy Outcome
1 Bilateral cerebral hemi‑
sphere, right temporal 
lobe
No 32.4 Gy IFO + VM26, 4 cycles Died
2 Right frontal lobe Partial resection 25.4 Gy TMZ + CPT‑11, 2 cycles; VIP, 
5 cycles
Died
3 Bilateral frontal lobes No 25.2 Gy No Died
4 Right temporal lobe Complete resection 27.0 Gy whole brain 
cranial irradia‑
tion + 30.0 Gy localized 
irradiation
CPT‑11 + TMZ, 6 cycles;  
CPT‑11 + Bevacizumab, 
1 cycle
Currently alive for 
47 months
5 Right frontal lobe, left  
cerebellum, left frontal 
lobe, spinal cord
Partial resection of the 
right frontal lobe
30.0 Gy localized irra‑
diation + 30.0 Gy spinal 
cord irradiation
CPT‑11 + TMZ, 2 cycles;  
CPT‑11 + Nedapl‑
atin + VCR, 5 cycles
Currently alive for 
29 months
6 Left cerebellum, medulla No 30.0 Gy localized irradia‑
tion
CPT‑11 + VCR + TMZ, 4 
cycles; VIP, 1 cycle
Still alive for 30 months
7 Left frontal lobe No No CPT‑11 + TMZ, 1 cycle Died
8 Left parietal lobe No No CPT‑11 + TMZ, 2 cycles; CPT‑
11 + Bevacizumab, 1 cycle
Died
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4 neuroblastoma and was 20.0% (11/55) in patients with 
disease relapse or progression (Table 2).
The 11 patients who developed brain metastases after 
multidisciplinary treatment had bone marrow involve-
ment at the initial diagnosis; two of 11 received ASCT at 
initial treatment; in addition, the MYCN amplification was 
detected in two of these patients. After multidisciplinary 
treatment before brain metastasis occurred, 8 patients 
achieved CR, 1 achieved PR, and 2 had SD. The median 
interval from the initial diagnosis to the development of 
brain metastasis was 18 months (range 6–32 months). The 
frontal and temporal lobes were the most common sites 
of brain recurrence or metastasis, as observed in 10 of 11 
patients. One patient had concurrent cerebellar metasta-
sis, and 1 had metastasis to the medulla oblongata.
Outcomes of 11 neuroblastoma patients with metastasis 
to the CNS after treatment
Of the 11 patients with CNS metastasis, 3 died at 1, 18, 
and 30  days, respectively, after giving up treatment; 8 
received salvage therapy as shown in Table 1.
Of the 8 patients who were treated with salvage chem-
otherapy, 2 patients with MYCN amplification died: 1 
died 3  months after the time of the detection of brain 
metastasis, and 1 died 10  months after the detection 
of brain metastasis; of the 5 patients without MYCN 
amplification, 3 were still alive at the last follow-up, and 
2 died. One patient with unknown MYCN status died 
(Table 1).
Survival time from CNS metastasis
After a median follow-up time of 24  months, 8 
of the 11 patients died from tumor progression. 
The remaining 3 patients were alive for 29, 30, and 
47 months, respectively, after the initiation of multi-
disciplinary therapy. The median OS was 25  months 
(range 9–47 months) for the 11 patients. The median 
interval from the initial diagnosis to the develop-
ment of brain metastasis was 18  months (range 
6–32 months). The median survival after the develop-
ment of metastases in the CNS was 4 months (range 
1 day to 29 months).
Table 2 Comparison of the clinical characteristics between relapsed patients with and without brain metastasis
CR complete response, PR partial response, SD stable disease.
a For MYCN status, 4 of 11 patients with brain metastasis and 27 of 44 patients without brain metastasis had no available data.
b Of 44 patients without brain metastasis, 2 had no data of lactate dehydrogenase. Two and ten patients in group with brain metastasis and without brain metastasis 
respectively underwent autologous stem cell transplant.
Variable Patients with brain metastasis Patients without brain metastasis P value
Total (cases) 11 44
Age (years)
 Median 4 5 0.073
 Range 2–10 1–10
Sex (cases)
 Male 8 30 0.632
 Female 3 14
MYCN status (cases)a
 Positive 2 6 0.572
 Negative 5 11
Bone marrow involvement (cases)
 Yes 11 35 0.101
 No 0 9
Lactate dehydrogenaseb
 Median (U/L) 568 353 0.076
 Range (U/L) 197–3,906 188–3,903
 0–500 U/L (cases) 6 23 0.533
 501–1,000 U/L (cases) 4 10
 >1,000 U/L (cases) 1 9
Tumor response (cases)
 CR 8 34 0.719
 PR 1 6
 SD 2 4
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Discussion
Neuroblastoma is the most common extracranial solid 
tumor in children. Although multidisciplinary treat-
ment including chemotherapy, surgery, radiotherapy, 
ASCT, and maintenance therapy with 13-cis-retinoic 
acid can induce the complete remission of high-risk neu-
roblastoma, most patients die from relapse and metasta-
sis. Metastasis to the brain, which is a site of relapse or 
progression, is one such cause of death. In this study, we 
analyzed the incidence, clinical characteristics, and prog-
nosis of brain metastases in cases of neuroblastoma in 
the absence of anti-GD2 monoclonal antibodies.
Our study indicated that the incidence of brain metas-
tasis in patients with high-risk neuroblastoma was 10.4% 
(11/106). For the high-risk neuroblastoma patients who 
achieved a first CR or PR or had SD, the incidence of 
brain metastasis was 20.0% (11/55). All of the patients 
with brain metastases had bone marrow involvement. 
The median age of the 11 patients with brain metasta-
ses was younger than the age of the patients without 
brain metastasis. Three patients were alive at 29, 30, and 
47  months, respectively, after the initiation of multidis-
ciplinary therapy. The median OS was 25 months (range 
9–47 months) for the 11 patients, and the median inter-
val from the initial diagnosis to the development of brain 
metastasis was 18  months (range 6–32  months). The 
median survival after the development of CNS metasta-
sis was 4 months (range 1 day to 29 months). Metastatic 
sites were located primarily in the frontal and temporal 
lobes.
The cooperative clinical trials in advanced countries 
have shown that the overall incidence of CNS metasta-
sis increased from 1.7% to 11.7% in patients who were 
treated with protocols from N4-N5 to N6-N7 and had 
prolonged survival [3]. With respect to chemotherapy, 
the Memorial Sloan-Kettering Cancer Center uses 
cycles of cisplatin, etoposide, cyclophosphamide, doxo-
rubicin, and vincristine to treat patients with high-risk 
and metastatic neuroblastoma [8]. Post-N4 and post-N5 
consolidation therapy consists of high-dose melpha-
lan- or thiotepa-based chemotherapy with autologous 
bone marrow rescue [9]. The consolidative treatment 
with N6 and N7 protocols involves immunotherapy with 
the anti-GD2 murine monoclonal antibody 3F8, either 
alone or labeled with 131I. The survival of patients with 
high-risk neuroblastoma increased to >38%. Of the 127 
newly diagnosed patients with stage 4 neuroblastoma, 8 
(6.3%) developed isolated CNS metastasis [9]. Our can-
cer center treated patients with high-risk neuroblastoma 
with similar chemotherapy protocols but without the 
anti-GD2 murine monoclonal antibody. In our study, the 
survival of patients was improved, but brain metastasis 
occurred more frequently. Paulino et al. [6] reported that 
brain metastases developed in 8% (9 of 113) of neuro-
blastoma patients. In our study, 11 patients with stage 4 
neuroblastoma developed brain metastases after receiv-
ing multidisciplinary treatment and had bone marrow 
involvement but had not brain metastasis at the initial 
diagnosis. The incidence of brain metastasis in our center 
was slightly higher than that in other developed coun-
tries. High-intensity chemotherapy and ASCT failed 
to prevent CNS relapse or progression, although high-
intensity chemotherapy prolonged the survival of high-
risk patients with neuroblastoma [10, 11]. Among our 
patients with brain metastasis, 2 patients received ASCT 
at initial therapy and 1 case also received anti-GD2 
antibody in Hong Kong University after ASCT. These 
patients still relapsed and had brain metastasis. It was 
similar to the report from Choi [11] that 4/11 had brain 
metastasis after CD34(+) transplantation.
The risk factors associated with the development of 
brain metastasis in neuroblastoma patients are contro-
versial. Lumbar puncture, high levels of serum lactate 
dehydrogenase (LDH), and orbital metastases at the time 
of diagnosis were associated with brain metastasis [8]. 
Based on the limited number of patients in our center, 
age and bone marrow involvement at initial diagnosis 
were associated with the subsequent development of 
brain metastasis, although the difference was not statis-
tically significant between the groups with and without 
brain metastasis. We hypothesized that the hematog-
enous spread from infiltrated bone marrow may break 
through the immature blood–brain barrier (BBB) and 
develop into brain metastases. The level of LDH has also 
been determined to be a prognostic factor [10]. A high 
level of serum LDH was found to represent in the patients 
with a higher tumor burden. Kramer et al. [8] found that 
elevated serum LDH (>1,500 U/mL) was also a significant 
risk factor for brain metastasis. The difference in LDH 
levels was not statistically significant between the two 
groups with and without brain metastasis in our study. 
It may be that the patients with higher levels of serum 
LDH died prior to the development of brain metastasis. 
Our results indicated no significant difference in MYCN 
amplification between the groups with and without brain 
metastasis. Further studies will be necessary to test the 
role of MYCN amplification in the development of brain 
metastasis. The MYCN amplification was associated with 
an advanced stage of neuroblastoma and rapid progres-
sion [12]. Some patients with MYCN amplification died 
before the development of brain metastasis. In our study, 
2 patients with MYCN amplification died 3 months after 
brain metastasis, suggesting that MYCN amplification 
facilitates tumor growth and metastatic potential.
Traditionally, neuroblastoma patients with brain 
metastasis had a poor prognosis, and in China, parents 
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of these patients tended to refuse further therapy once 
brain metastasis was diagnosed. Based on a set of limited 
cases, we found that patients with isolated CNS metasta-
sis whose brain lesions were completely resected or dem-
onstrated a good response to chemotherapy like other 
chemo-sensitive CNS tumors, for example CNS germ 
cell tumors [13], had a better prognosis and a prolonged 
survival. In our study, 3 patients with brain metastasis 
are alive after salvage therapy. Bone marrow infiltration 
of Patient 4 resolved soon after chemotherapy. He under-
went complete removal of brain tumor, cranial radio-
therapy 20 days following surgery and achieved a CR; his 
mental and motor statuses remained normal until the last 
follow-up, and he returned to school. The other 2 surviv-
ing patients underwent incomplete resection of the brain 
metastases and survived with tumors.
The combination of vincristine, temozolomide, and 
irinotecan (VIT) was effective against refractory neu-
roblastoma [14]. The regimen VIT can cross the BBB. If 
temozolomide is administered 1  h prior to irinotecan, 
the two agents have a synergetic antineoplastic activ-
ity for brain and bone marrow metastases. Irinotecan is 
a camptothecin prodrug, and its active metabolite (SN-
38) inhibits the nuclear enzyme topoisomerase I. The 
temozolomide-induced formation of O6-methylguanine 
adducts alkylate or methylate  DNA, and therefore it 
facilitates the creation of topoisomerase I/DNA com-
plexes. The concentration of temozolomide in the serum 
reaches its peak 1 h after administration, suggesting that 
DNA-methylating agents could potentially augment the 
activity of camptothecins [14]. Four patients achieved PR 
after receiving VIT chemotherapy. Patient 4 responded 
well to chemotherapy with irinotecan, resulting in CR in 
the bone marrow and disease-free survival of 47 months. 
Kramer et  al. [15] evaluated the addition of compart-
mental intrathecal antibody-based radioimmunotherapy 
(cRIT) in neuroblastoma patients with metastatic CNS 
neuroblastoma following surgery, craniospinal irra-
diation, and chemotherapy; finally, 17 of the 21 patients 
who were treated with cRIT salvage therapy were alive 
7–74 months (median 33 months) after CNS relapse, and 
the remaining patients were free of CNS metastasis.
Our study had some limitations. The detection of 
MYCN status was not previously performed in all 
patients. Immunotherapy that targets the molecules 
expressed in neuroblastoma cells warrants further inves-
tigation and may be used to prevent brain metastasis.
Conclusions
In summary, our study suggests that the incidence of 
brain metastasis increased in neuroblastoma patients 
with a prolonged survival. High-risk factors may include 
bone marrow involvement and a younger age at initial 
diagnosis. Patients with brain lesions that are completely 
resected and those with a CR to chemotherapy and radi-
otherapy in terms of resolution of bone marrow involve-
ment may have a better prognosis.
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